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The etiology of squamous cell carcinomas of the head and neck (HNSCC) is 
considered to be multifactorial. Besides the main risk factors of tobacco and alcohol, 
infection by human papillomavirus (HPV) and genetic alterations are likely to play a 
role. Oncogenic HPVs are a causative agent in uterine cervical cancer, and molecular 
biology approaches have provided evidence for specific mechanisms. The role of 
HPV infection in head and neck carcinogenesis is less well established. HPV DNA 
has been repeatedly detected in HNSCC, especially in squamous cell carcinomas of 
tonsils. Little is known about HPV infection in tumor-free tonsils. 
To investigate the role of tumor suppressor genes, PTEN and LKB1, in laryngeal 
tumorigenesis, we analyzed somatic mutations of these genes from laryngeal 
carcinoma and laryngeal papillomatosis by genomic sequencing and single strand 
confirmation polymorphism assay, respectively. We observed no mutation in these 
two genes in our studied samples.  
In an attempt to elucidate HPV status in head and neck carcinomas, we studied 
the frequency of HPV DNA and viral genotypes in HNSCC by means of SPF10 PCR 
and INNO-LiPA hybridization. We found that more than half the patients harbored 
HPV DNA in their HNSCC samples, and oncogenic HPV-16 was predominant. Copy 
numbers of viral E2 and E6 genes in the HPV-16 positive HNSCC samples were 
quantitated by real-time PCR. We observed a considerable variation in the viral copy 
numbers among different samples, and tonsillar carcinomas had a remarkably 
higher viral load than did carcinomas in the other sites of the head and neck region. 
HPV-16 existed in episomal, integrated, or mixed forms and tumors harboring only 
episomal virus were significantly larger in size at diagnosis than those with only 
integrated or mixed forms. The presence of HPV DNA did not correlate with a better 
prognosis in HNSCC patients. 
Furthermore, we also observed that 6% of patients with tonsillitis or tonsillar 
hypertrophy harbored oncogenic HPV-16 but no other types in their tonsillar tissue, 
as determined by a sensitive nested PCR assay. The presence of HPV-16 DNA in 
tonsils did not correlate with serum antibodies against viral proteins. Our findings 
imply that tonsillar epithelial cells serve as a reservoir for HPV-16 virus.  
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To establish an in vitro model to study mechanisms involved in HPV-associated 
tonsillar carcinogenesis, normal human tonsillar epithelial (HTE) cells were 
transfected with full-length HPV-16 DNA. All the transfected HTE cell lines were 
cytogenetically abnormal. They exhibited altered morphology and impaired 
expression of cytokeratins in organotypic culture. They failed to form colonies in soft 
agarose and formed no tumors in nude mice within 6 months. They have been 
cultured over 100 passages and considered as immortalized cell lines and thus 
provide a useful model for studying further the multistep molecular events of HPV-
16 associated tonsillar carcinogenesis. 
Original publications 7
2. ORIGINAL PUBLICATIONS 
This thesis is based on the following original studies, which are referred to in the text 
by their Roman numerals. 
I. Chen RW, Avizienyte E, Roth S, Leivo I, Mäkitie AA, Aaltonen L-M, Aaltonen 
LA. PTEN and LKB1 genes in laryngeal tumors. J Med Genet 1999; 36; 943-4.
II.  Koskinen W*, Chen RW*, Leivo I, Mäkitie A, Bäck L, Kontio R, Suuronen R, 
Lindqvist C, Auvinen E, Molijn A, Quint WG, Vaheri A, Aaltonen L-M. 
Prevalence and physical status of human papillomavirus in squamous cell 
carcinomas of the head and neck. Int J Cancer 2003; 107; 401-6. *These two 
authors contributed equally to this article. 
III.
IV. Chen RW, Aalto Y, Teesalu T, Dürst M, Knuutila S, Aaltonen L-M, Vaheri A. 
Establishment and characterization of human papillomavirus type 16 DNA 
immortalized human tonsillar epithelial cell lines. Eur J Cancer 2003; 39; 698-
707.
The original publications are reproduced with the permission of the copyright 
holders.
tonsillar tissue.
Chen RW, Sehr P, Waterboer T, Pawlita M, Leivo I, Vaheri A, Aaltonen L-M. 
Presence of DNA of human papillomavirus 16 but no other types in tumor-free 
Resubmitted (J Clin Microbiol)
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3. ABBREVIATIONS AND DEFINITION OF SOME ESSENTIAL TERMS 
AJC   American Joint Cancer Committee 
ATCC   American Type Culture Collection 
DEIA   DNA enzyme immunoassay 
E    early (gene) 
EGF   epidermal growth factor 
FISH   fluorescence in situ hybridization 
HES   human embryonic skin 
HNSCC  squamous cell carcinoma of the head and neck 
HPV   human papillomavirus 
HTE   human tonsillar epithelium 
IARC   International Agency for Research on Cancer 
IHC   immunohistochemistry  
ISH    in situ hybridization 
kb    kilobase(s) 
L    late (gene) 
LiPA   line probe assay 
MMAC   mutated in multiple advanced cancers  
NCR   non-coding region 
ORF   open reading frame 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PTEN   phosphatase and tensin homolog gene
SCC   squamous cell carcinoma 
SPF    short PCR fragment  
SSCP   single strand confirmation polymorphism 
LKB1/STK11 serine/threonine kinase 11 
UICC   International Union Against Cancer 
VLP   virus-like particle 
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EPISOMAL VIRUS – viral DNA exits extrachromosomally in a cell. 
INTEGRATED VIRAL GENOME – a viral genome which is incorporated into the 
cellular DNA and is replicated with it. 
INTEGRATION – the process of insertion of viral DNA into the host genome. It 
usually involves a virus-coded enzyme, the integrase. The viral DNA is then 
replicated by the host nucleic acid replication mechanism.  
TRANSFECTION – Two different approaches serve to transfer DNA into eukaryotic 
cells: transient transfection and stable transfection. In transient transfection, 
recombinant DNA is introduecd into a recipient cell line in order to obtain a 
temporarily but high level of expression of the target gene. The transfected DNA 
does not necessarily become integrated into the host chromosome. Stable 
transfection is used to establish clonal cell lines in which the transfected target gene 
is integrated into chromosomal DNA.  
FISH – This procedure describes fluorescence in situ hybridization of biotin- or 
digoxygenin-labeled probes to denatured metaphase chromosomes and interphase 
nuclei. The hybridized probes are detected and visualized with fluorochrome-
conjugated reagents.
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4. INTRODUCTION 
The etiology of squamous cell carcinomas of the head and neck (HNSCC) is 
considered to be multifactorial. Besides the main risk factors, tobacco use and 
alcohol intake (Decker and Goldstein 1982; Franceschi et al 1990), infection by 
oncogenic human papillomavirus (HPV) as well as genetic alterations are likely to 
play a role in it. Several tumor suppressor genes play a role in human 
tumorigenesis. Somatic mutations of the PTEN gene, a major new tumor 
suppressor gene located at human chromosome 10q23, have been found in several 
types of cancers, including gliomas and glioblastoma, as well as carcinomas of 
prostate, kidney, and breast (Daniel et al 1995; Fallani et al 1997; Steck et al 1997). 
Germline mutations in LKB1, a tumor suppressor gene mapped to 19p13.3, have 
been associated with Peutz-Jeghers syndrome (PJS) (Hemminki et al 1998; Jenne et 
al 1998) whereas somatic mutations in this gene are a rare event in most sporadic 
tumors (Avizienyte et al 1998; Avizienyte et al 1999; Bignell et al 1998; Park et al
1998; Resta et al 1998). Little is known about the role of PTEN and LKB1 genes in 
the development of laryngeal tumors, among which approximately 25% (range 0 
to 100%) of laryngeal carcinomas are associated with infection of oncogenic HPVs
and 83 to 100% of the laryngeal papillomatosis are associated with infection by 
HPV types 6 or 11 (Syrjänen and Syrjänen 2000; Aaltonen et al 2002).
HPVs are small double-stranded DNA viruses infecting epithelial cells of the 
skin, as well as anogenital and oropharyngeal mucosa. To date, 96 HPV genotypes 
have been identified and fully sequenced (de Villiers et al 2004). An increasing 
number of studies have reported on the presence of HPV in HNSCC; its frequency 
varies greatly, depending on the number of patients included and tumor site, as 
well as detection methods applied. By a sensitive PCR, the overall prevalence of 
HPV DNA in HNSCC has been reported from 9 to 60% and the majority of HPV-
positive tumors contained the high-risk HPV-16 (Snijders et al 1996; Paz et al 1997; 
McKaig et al 1998; Gillison et al 2000; Mork et al 2001). Sero-epidemiological data 
showed that a significantly increased risk of HNSCC is associated with HPV-16 
seropositivity (Schwartz et al 1998; Mork et al 2001; Herrero et al 2003). The 
prevalence of HPV, particularly the high-risk types, suggests a causal association 
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between HPV and a subset of HNSCC (Gillison et al 2000; Herrero et al 2003; Dai et 
al 2004; Smith et al 2004). HPV is more commonly found in squamous cell 
carcinoma (SCC) of the tonsil than at other sites of HNSCC (Snijders et al 1992; 
Paz et al 1997; Klussmann et al 2001; Mellin et al 2000). The reason for the close 
association of HPV with tonsillar SCC remains unclear. Investigation of HPV 
infection in the tumor-free tonsils would additionally elucidate the role of HPV in 
tonsillar carcinogenesis. 
Oncogenic HPVs play an etiological role in cervical cancer, and molecular 
biological approaches have provided evidence for specific carcinogenic 
mechanisms. Besides the most-studied tumor suppressor proteins p53 and pRb, 
which are degraded by the viral oncoproteins E6 and E7, respectively, several other 
cellular proteins have also been found to interact with these two viral 
oncoproteins (Mantovani and Banks 2001; Munger et al 2001; Scheffner and 
Whitaker 2003). Study of HPV in cell culture has been hindered because a 
complete viral life cycle cannot be mimicked in vitro. Although terminal 
differentiation of squamous epithelial cells has been achieved by use of a raft 
culture system, infectious virion production is very limited (Meyers et al 1992; 
Meyers et al 2002). Transfection of primary human epithelial cells with high-risk 
types of HPV DNA often results in cell transformation and immortalization 
(McDougall 1994). The HPV-immortalized cell lines such as human cervical 
epithelial cells and foreskin keratinocytes, as well as the naturally infected cell 
lines UT-Dec-1 and W-12 have served as an in vitro model for studying the role of 
HPV in human carcinogenesis (Dürst et al 1987a; Stanley et al 1989; Zheng et al
1994; Hietanen et al 1998). To establish an HPV-immortalized tonsillar epithelial 
cell line may provide a useful in vitro model to study HPV in tonsillar 
carcinogenesis.  
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5. REVIEW OF THE LITERATURE 
5.1. HUMAN PAPILLOMAVIRUS 
Human papillomaviruses (HPVs) belong to the Papillomaviridae family and are 
small, nonenveloped, icosahedral DNA viruses. The viral particles are 55 to 60 nm 
in diameter and consist of a single molecule of a double-stranded covalently 
closed circular DNA genome of approximately 7900 bp. The genomic organization 
of all papillomaviruses is remarkably similar (Fig 1). Viral DNA is associated with 
cellular histones to form a chromatin-like complex. All coding sequences are 
located on one DNA strand only. Most papillomaviruses contain six early ORFs 
and two late ORFs. There is a region with no ORFs which is designated the long 
control region (LCR), the upstream regulatory region (URR), or the noncoding 
region (NCR).  
Figure 1. Genomic organization of HPV-16. ORFs deduced from the DNA sequence are 
designated E1 to E7, L1, and L2, indicated in grey boxes. A non-coding region (NCR) is 
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5.1.1. Classification of human papillomaviruses 
Genotypes
Determination of HPV genotypes is based on their degree of homology within the 
L1 ORF (de Villiers 1997). If the DNA sequence of the L1 ORF of a new isolate 
differs by more than 10% from the closest related known type, it is regarded as a 
novel type; a difference between 2 and 10% is referred to as a subtype; and at less 
than 2%, a variant, as agreed at the International Papillomavirus Workshop held 
in Quebec in 1995 (zur Hausen 1996). Thus far, 96 HPV genotypes have been fully 
sequenced and identified (de Villiers et al 2004). 
Mucosal and cutaneous types 
Depending on the location of the lesion from which a specific HPV type was first 
isolated, HPV can be classified as mucosal or cutaneous types. HPV types 
associated with skin warts are for example HPV-1, -2, and -4. A wide range of 
HPV types including HPV-5, -8, -9, -23, and -47 cause epidermodysplasia 
verruciformis lesions, which can be transformed to malignancy upon exposure to 
ultraviolet light (Androphy 1994; Pfister 2003). The largest subgroup is 
represented by HPV types infecting mainly mucosal surfaces of the genital and 
respiratory tracts. More than 40 of the identified HPV types belong into this group 
(de Villiers 1997).
High- and low-risk types 
Classification of HPVs can be extended to cover the carcinogenic potential of 
different virus types. According to a recent publication by Munoz and colleagues, 
15 are classified as high-risk types including HPV-16, -18, -31, -33, -35, -39, -45, -51, 
-52, -56, -58, -59, -68, -73, and -82; 3 are classified as probable high-risk types 
which are HPV-26, -53, and -66; low-risk types consist of HPV-6, -11, -40, -42, -43, -
44, -54, -61, -70, -72, -81, and CP6108 (Munoz et al 2003). 
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5.1.2. HPV life cycle 
HPV has a specific tropism for squamous epithelial cells. Several modes of viral 
DNA replication during the infection were suggested in a review (Chow and 
Broker 1994) and are elucidated in Fig 2. Thus, HPV proteins stimulate the 
proliferation of cells and interfere with normal epithelial cell differentiation, 
leading to an increased thickness of the infected epithelial cells which produces 
neoplasia.
Figure 2. Schematic representation of HPV life cycle in stratified epithelium. 
(1) HPV infects basal cells of the squamous epithelium through micro-
abrasions, and wound-healing promotes the proliferation of basal cells and 
activates the expression the viral early genes, resulting in a temporary 
amplification of the viral DNA; (2) after wound healing, most basal cells 
return to a quiescent state and divide infrequently, and viral transcription 
and replication are autoregulated at a low level, resulting in a steady-state, 
low-level maintenanence mode; (3) after a cell leaves the cell cycle and 
undergoes progressive differentiation, a vegetative amplification mode for 
the production of progeny virus occurs. 
5.1.3. Function of viral proteins 
E1 and E2 proteins 
The E1 protein has site-specific DNA-binding functions and it binds to the origin 
of replication in the NCR (Ustav et al 1991; Holt et al 1994). The E2 open reading 
frame (ORF) encodes at least two or three different proteins which all act as 
transcription factors and regulate viral transcription (Cripe et al 1987; Baker et al
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replication (Chow and Broker 1994). During early stages of viral infection, the E2 
protein represses transcription of the oncogenes E6 and E7 (Thierry and Howley 
1991). Integration of the viral genome, which often takes place during 
carcinogenic progressing, disrupts the E2 and E1 ORFs and results in elevated 
expression of E6 and E7 (Jeon and Lambert 1995). 
E4 protein 
The E4 ORF is located in an early gene region, yet it appears to be expressed as a 
late gene with a role in productive infection. It is exclusively localized within the 
differentiating layer of the infected epithelium and induces the collapse of the 
cytokeratin network (Doorbar et al 1991; zur Hausen 1996).  
E5 protein
The E5 of HPV-16 is a small hydrophobic polypeptide and with weak 
transforming activity (Leptak et al 1991; Pim et al 1992). The E5 ORF is often 
disrupted in cervical cancer and does not seem to be essential for maintaining the 
malignant phenotype but is possibly important for initiation of transformation 
(Schwarz et al 1985; zur Hausen 1996). The E5 stimulates the transforming activity 
of the epidermal growth factor receptor resulting in increased cell proliferaction 
(Pim et al 1992). In a raft culture model, the E5 was shown to support cellular 
DNA synthesis in suprabasal cells and neither viral late gene expression nor 
epithelial differentiation was affected by the E5 (Genther et al 2003). The E5 
protects human foreskin keratinocytes from ultraviolet B-irradiation-induced 
apoptosis (Zhang et al 2002). On the other hand, it sensitizes human keratinocytes 
to apoptosis induced by osmotic stress (Kabsch and Alonso 2002).  
E6 protein 
The E6 protein of HPV-16 is a small polypeptide of approximately 150 amino 
acids. It contains two zinc-binding domains, each of which contains two copies of 
a Cys-X-X-Cys motif (Barbosa et al 1989). The E6 protein first binds to a cellular 
ubiquitin-ligase, the E6-associated protein (E6-AP) forming a complex which is 
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then able to bind the p53 protein, resulting in p53 degradation mediated by the 
cellular ubiquitin proteolysis system (Werness et al 1990; Scheffner et al 1990; 
Scheffner et al 1993). Because p53 is required for the growth arrest following 
cellular DNA damage, cells without functional p53 are not arrested appropriately 
in G1, but display genomic instability (Werness et al 1990). The HPV-16 E6 protein 
activates telomerase (Klingelhutz et al 1996), an enzyme that maintains the 
telomeric DNA at the ends of linear chromosomes (Greider and Blackburn 1985). 
Without telomerase, telomers shorten upon each cell division, until they reach a 
critically short length. Beyond this point further division would induce damage in 
the coding regions of the chromosome and cause cell senescence. Telomerase 
activity is undetectable in most normal human somatic cells, but nearly all human 
cancers and immortalized cell lines have highly active telomerase (Kim et al 1994; 
Shay and Bacchetti 1997). Besides the p53 and telomerase, the E6 proteins also 
interact with various cellular proteins (Table 1). 
E7 protein 
The E7 protein of HPV-16 is a small, predominantly nuclear polypeptide of 
approximately 100 amino acids. Interestingly, the carboxy terminus of E7 contains 
a similar zinc-binding domain as the E6. The E7 binds to retinoblastoma protein 
(pRB) and the related pocket proteins p107 and p130, results in releasing the 
transcription factor E2F from pRB complexes, and consequently activating genes 
regulating cell proliferation (Dyson et al 1989; Bagchi et al 1990; Bandara et al
1991). Besides the pRb, the E7 also interacts with various proteins (Table 1), most 
of which are important regulators of cell growth, expecially the transition of a cell 
from the G1 to the S-phase of mitosis. The E7 protein has recently been shown to 
induce abnormal centrosome duplication, resulting in multipolar, abnormal 
mitoses, aneuploidy, and genomic instability, one of the hallmarks of a cancer cell 
(Duensing et al 2000; Duensing et al 2001). This function of E7 as a mitotic mutator 
may directly contribute to generating the host chromosomal changes that are 
necessary for carcinogenic progression of a high-risk HPV positive precursor 
lesion.
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Table 1. List of HPV-16 oncoproteins associated cellular proteins 
Viral 
oncoproteins 
Cellular proteins Reference 
E6-associated protein, p53 Werness et al 1990; Scheffner and 
Whitaker 2003 
telomerase Klingelhutz et al 1996 
hTERT Kiyono et al 1998; Gewin and Galloway 
2001
homolog of disc large (hDlg) Lee et al 1997; Kiyono et al 1997; Gardiol
et al 1999 
human Scribble (Vartul) Nakagawa and Huibregtse 2000 
MUPP1 Lee et al 2000 
MAGI-1, -2, -3 Glaunsinger et al 2000; Thomas et al 2002
E6
Myc Veldman et al 2003 
pRb, p107, p130 
Dyson et al 1989; Bagchi et al 1990; 
Bandara et al 1991; Scheffner and 
Whitaker 2003 
AP-1 transcription factors (c-
Jun, JunB, JunD, c-Fos) 
Antinore et al 1996 
cyclin-dependent kinase 
inhibitors (p21, p27) 
Funk et al 1997; Zerfass-Thome et al 1996;
Jones et al 1997 
histone deacetylases 
complexes (HDAC) Brehm et al 1999 
cyclins  and Cdks Chakrabarti and Krishna 2003 
E7
pCAF Avvakumov et al 2003 
Both E6 and E7 proteins play a role in cell transformation and immortalization. 
The E6 protein alone cannot immortalize human foreskin keratinocytes (Halbert et 
al 1991), but it is capable of immortalizing human mammary epithelial cells (Band
et al 1991; Band et al 1993; Liu et al 1999) and inducing carcinomas in transgenic 
mice (Song et al 1999). The E7 alone is capable of immortalizing human foreskin 
keratinocytes (Halbert et al 1991). However, the E6 and E7 together can 
immortalize human epithelial cells cooperatively (Hawley-Nelson et al 1989; 
Munger et al 1989). In E6- and E7-transgenic mice experiments, the E7 primarily 
causes tumor promotion, whereas the E6 contributes weakly to the early stages, 
acts more strongly during tumor progression, and accelerates the malignant 
conversion of benign tumors (Song et al 2000).
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Late proteins 
The L1 and L2 proteins are 72 capsomers encapsidating viral DNA. The L1 is the 
major capsid protein, with an average molecular mass of 57 KDa, and it contains 
reactive epitopes for type-specific neutralization. The L2 protein is a minor 
component of the viral capsid with an about 78 kDa polypeptide (Doorbar and 
Gallimore 1987).  
5.2. HISTORICAL  BACKGROUND OF HPV AND CANCER 
The hypothesis of infectious etiology of the common wart was shown by Ciuffo, 
who demonstrated in 1907 that cell-free extracts from common warts were 
transmissible from person to person upon intradermal inoculation, as reviewed in 
(zur Hausen 1999a). Papillomavirus as a carcinogen was first reported by Drs. 
Rous and Beard in 1934 (zur Hausen 1999a). It was not until the mid 1970s that 
HPV was singled out to be the most likely candidate for the cause of cervical 
cancer (zur Hausen et al 1974; zur Hausen 1976), and from 1983 to 1986, HPV-16, -
18, -31, and -33 were isolated from cervical cancer and its precursors (Dürst et al
1983; Boshart et al 1984; Lorincz et al 1986; Beaudenon et al 1986). In 1995, the 
International Agency for Research on Cancer (IARC) concluded that there was 
sufficient evidence to categorize HPV types 16 and 18 as human carcinogens 
(IARC 1995). An association between HPV and a subset of head and neck cancer 
was noticed already in the 1980s (Syrjänen et al 1982; Syrjänen et al 1983a; Löning
et al 1985; de Villiers et al 1985). 
5.3. PTEN AND LKB1 TUMOR SUPPRESSOR GENES 
PTEN (also known as MMAC1) is a major new tumor suppressor gene located at 
human chromosome 10q23 (Steck et al 1997). It comprises 9 exons with a coding 
sequence of 1212 bp and encodes a 403 amino acid phosphatase protein that 
shares sequence homology with the dual-specificity phosphatase family (Li and 
Sun 1997). PTEN is a tumor suppressor gene based on the presence of inactivating 
mutations in human brain, breast, and prostate cancers (Li et al 1997; Steck et al
1997). Further studies extended initial observations in a variety of different tumor 
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entities. Somatic mutations of this gene occur in several types of cancers, 
including gliomas and glioblastoma, as well as prostate, kidney and breast 
carcinomas (Fallani et al 1997; Daniel et al 1995; Steck et al 1997). Germline 
mutations of PTEN gene underlie Cowden disease, an autosomal dominant 
disorder associated with an increased risk for breast and thyroid cancer, and 
possibly also for endometrial malignancy (Liaw et al 1997). In addition, multiple 
oral papillomas are associated with Cowden’s disease (Greer et al 1976).  
LKB1 (also called STK11) is a tumor suppressor gene mapped to 19p13.3, and it 
encodes a serine/threonine kinase which is highly homologous (84%) to Xenopus 
serine/threonine kinase XEEK1 (Su et al 1996). Germline mutations in the LKB1
gene have been associated with Peutz-Jeghers syndrome (PJS) (Hemminki et al
1998; Jenne et al 1998), which is characterized by hamartomatous intestinal 
polyposis, mucocutaneous pigmentation, and increased risk for cancer of multiple 
organ systems (Phillips et al 1994). Somatic mutation in LKB1 is a rare event in 
most sporadic tumor types: melanoma, pancreatic, gastric, ovarian granulose, 
cervical, lung, soft tissue, renal tumors, colorectal, testicular, breast, gastric 
carcinoma, and colon cancer (Avizienyte et al 1998; Avizienyte et al 1999; Bignell et 
al 1998; Park et al 1998; Resta et al 1998). Thus far, reports on the mutation analysis 
of this gene in HNSCC are few.
5.4. SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK 
Squamous cell carcinoma of the head and neck (HNSCC) is a group of malignant 
epithelial diseases arising from the mucosa of the upper aerodigestive tract 
including the lips, oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, 
maxillary sinus, nasal cavity and ethmoid sinus, and salivary glands (Fig 3). This 
disease is characterized by local tumor aggressiveness, early recurrence, and high 
frequency of second primary tumors. HNSCC represents the eighth most 
prevalent malignancy worldwide, with nearly half a million new cases per year 
(Parkin et al 1999). According to the report by Finnish Cancer Registry in 2002, 
each year approximately 600 new cases of head and neck cancer are diagnosed in 
Finland, and the age-adjusted incidence rates is 10.7 per 100,000 in male and 3.8 
Human papillomavirus type 16 in head and neck carcinogenesis 20
per 100,000 in female (Finnish Cancer Registry 2002). Treatment of head and neck 
cancers is based on surgery or radiotherapy, or their combination, or on chemo-
irradiation (Luukkaa et al 2003; Forastiere et al 2003). 
Figure 3. Anatomic overview of head and neck region, modified from (Netter 
2001) in Plate 57. 
5.4.1. Etiology and risk factors for the head and neck cancer 
As many as 80 to 90% of all head and neck cancers except cancer of the salivary 
glands may be attributed to the known risk factors tobacco smoking and alcohol 
consumption (Decker and Goldstein 1982; Franceschi et al 1990; Spitz 1994; Licitra
et al 2002), although a minority of head and neck cancer patients have no history 
of tobacco or alcohol use, suggesting other possible contributing exposures 
(Gillison et al 1999). Several oncogene activations (Ras, Myc, epidermal growth 
factor receptor, and cyclin D1) and tumor suppressor gene inactivations (p53,
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p16INK4A, Rb) have been identified in primary HNSCC, as reviewed in (Forastiere et 
al 2001; Mao et al 2004). The p53 gene is probably the most widely studied gene in 
HNSCC. The reported frequency of p53 mutations in HNSCC varies widely, from 
30 to 70%, and this may be a reflection of the techniques used to detect mutations, 
the regions of p53 subjected to analysis, and differences in mutation rates between 
anatomical sites. Many studies analyzing gene sequence have focused on exon 5-8 
of p53, since the majority of mutations occur here (Gasco and Crook 2003; Blons 
and Laurent-Puig 2003). The frequency of p53 mutations in HNSCC seems to be 
correlated with the dose-dependant effect of tobacco and inversely associated 
with HPV infection, as reviewed in (Blons and Laurent-Puig 2003). The spectrum 
of chromosomal loss increased progressively at each histopathological step from 
benign hyperplasia to invasive cancer in HNSCC (Califano et al 1996). Viruses, 
mainly HPV and Epstein-Barr virus (EBV), have been noticed to be connected 
with head and neck cancer development. The association of infection with HPV 
and cancers of the oral cavity, larynx, and nasal and paranasal regions was 
originally reported in (Syrjänen et al 1982; Syrjänen et al 1983b; Syrjänen et al
1983a). The association of infection by EBV and nasopharyngeal carcinomas was 
first suggested by Old et al in 1960s, as reviewed in (zur Hausen 1999b).  
5.4.2. Tumor classification 
The International Union Against Cancer (UICC) TNM classification is identical to 
that of the American Joint Cancer Committee (AJC). The T categories are defined 
by tumor dimension, the N categories are according to whether the cancer has 
spread to the regional lymph nodes, and the M catogories indicate whether the 
cancer has any distant spreading metastasis (Table 2). Tumor stage is classified by 
adding the TNM data together (Table 3).  
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Table 2. Tumor classification for oropharyngeal cancer (UICC 2002) 
TNM Definition 
TX primary tumor cannot be assessed 
T0 no evidence of primary tumor 
Tis carcinoma in situ
T1 tumor # 2 cm 
T2 tumor > 2 cm but # 4 cm 
T3 tumor > 4 cm 
T4a tumor invades any of the following: larynx, deep/extrinsic musle 
of tongue, medial pterygoid, hard palate, or mandible 
T4b tumor invades any of the following: lateral pterygoid muscle, 
pterygoid plates, lateral nasopharynx, skull base; or it encases the 
carotid artery  
NX regional lymph nodes cannot be assessed 
N0 no regional lymph node metastasis 
N1 metastasis in a single ipsilateral lymph node # 3 cm 
N2a metastasis in a single ipsilateral lymph node > 3cm but # 6cm 
N2b metastasis in multiple ipsilateral lymph nodes # 6cm 
N2c metastasis in bilateral or contralateral lymph nodes, # 6cm 
N3 metastasis in a lymph node > 6 cm 
MX distant metastasis cannot be assessed 
M0 no distant metastasis 
M1 presence of distant metastases 
.
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Table 3. Tumor stage classification for oropharyngeal cancer (UICC 2002) 
TNM stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
III T3 N0, N1 M0 
IVA T1-T3 N2 M0 
IVA T4a N0-N2 M0 
IVB T4b any N M0 
IVB any T N3 M0 
IVC any T any N M1 
5.4.3. HPV in HNSCC 
To date, more than 1900 studies on the presence of HPV DNA in HNSCC have 
emerged. The frequency of HPV DNA in HNSCC has a large variation depending 
on tumor site, material and methods applied, as well as number of cases included, 
in average range from 9 to 60% (Snijders et al 1996; Paz et al 1997; McKaig et al
1998; Gillison et al 2000; Mork et al 2001). Several case-control studies as well as a 
meta-analysis suggested that high-risk HPVs are associated with HNSCC (Miller 
and Johnstone 2001) (Table 4). In situ hybridization (ISH) reveals that HPV DNA 
is located in tumor cells but not in the surrounding stroma or the nondysplastic 
surface epithelium in HNSCC (Niedobitek et al 1990; Gillison et al 2000). 
Klussmann et al documented for the first time that viral loads as determined by 
quantitative real-time PCR in microdissected HPV-16 positive tonsillar tumors 
were higher than in whole-sample DNA preparations, indicating that HPV DNA 
is present in the tumor and not in the stroma or other cells (Klussmann et al 2001). 
By the more sensitive PCR assay, however, HPV DNA has also been detected in 
tumor-free resection margins of HPV-positive HNSCC (Snijders et al 1996; 
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Badaracco et al 2000; Klussmann et al 2001). Approximately half the HPV DNA- 
positive HNSCC expresses E6/E7 mRNA in the tumors (Wiest et al 2002; Balz et al
2003). HPV DNA-positive tumors with no E6/E7 mRNA expression possibly 
underwent a deletion within the E6 gene (Wiest et al 2002). Interestingly, E6/E7 
mRNA expression occurs mostly in tumors with wild-type p53, reduced pRb, and 
overexpressed p16, whereas tumors without E6/E7 expression are associated with 
mutant p53, normal pRb, and low levels of p16 (Wiest et al 2002). HPV-16 E6 
transcript expression is correlated with basaloid morphology (van Houten et al
2001). A rather frequent coexistence of HPV DNA and p53 mutations was found 
in HNSCC (Barten et al 1995; Chiba et al 1996; Scholes et al 1997), which is in 
contrast to the situation in cervical and other anogenital cancers, which show an 
almost complete inverse correlation between HPV and p53 mutations and share a 
conspicuous basaloid morphology (zur Hausen 1996).  
Table 4. High-risk HPVs in HNSCC (case-control studies) 
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5.4.4. HPV in SCC of tonsils 
HPV DNA is detected in 42 to 100% of all cases of tonsillar carcinoma, thus 
appearing more frequently than in other head and neck carcinomas (Snijders et al
1992; Steinberg and DiLorenzo 1996; Paz et al 1997; Andl et al 1998; Gillison et al
2000; Mellin et al 2000; Mork et al 2001; Mellin et al 2002; Syrjänen 2004; Li et al
2004). Tonsillar SCC often contains episomal HPV with or without the deletion of 
E2 sequence (Mellin et al 2002). HPV-positive tonsillar SCC has been suggested as 
a distinct biological group by several studies. For instance, HPV-16 is 
predominant; it has rather frequent oncogene E6/E7 expression with wild-type 
p53 (Wiest et al 2002; Balz et al 2003), reduced pRb and cyclin D1 expression and 
increased p16 expression (Andl et al 1998; Wilczynski et al 1998; Klussmann et al
2003; Li et al 2004). Patients with HPV-positive tonsillar SCC are younger in age, 
use less tobacco and alcohol, and have better prognosis than do patients with the 
HPV-negative cancers (Mellin et al 2000; Strome et al 2002; Li et al 2003). 
Epidemiological data showed that patients with HPV-associated anogenital 
cancers had a 4.3-fold increased risk for tonsillar SCC, whereas patients with 
HPV-unrelated cancer (cancers of colon, stomach and breast) had no increased 
risk for developing tonsillar SCC, suggesting that HPV may be a common 
etiological factor for the link between tonsillar and anogenital SCC (Frisch and 
Biggar 1999). 
5.4.5. HPV DNA in tumor-free tonsils 
The detection of HPV DNA in tumor-free tonsils has been reported in only a few 
studies (Smith et al 1993; Watanabe et al 1993; Fukushima et al 1994; Tominaga et al
1996; Strome et al 2002) and others failed to detect the viral DNA in tonsillitis 
samples (Brandsma and Abramson 1989; Niedobitek et al 1990; Snijders et al 1992; 
Klussmann et al 2001). The overall frequency of HPV DNA in normal tonsillar 
mucosa or benign lesions is 8.5% (17 of 200), consisting of 70% with HPV-16 and 
30% with HPV-6/11, as summarized in a recent review (Syrjänen 2004). The 
reason for the association of HPV with the tonsil remains unclear. HPV seems to 
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be important, especially in tonsillar carcinogenesis, and data on HPV infection in 
tumor-free tonsils is based on small study populations.   
Presence of the IgG antibody to the HPV-16 L1 capsid protein is an indication 
of persistent infection, and presence of an antibody against HPV-16 E6 or E7 may 
suggest the HPV-associated malignancy (Herrero et al 2003; Zumbach et al 2000). 
Seroepidemiological data showed a significantly increased risk for HNSCC is 
associated with HPV-16 seropositivity (Mork et al 2001). Serum antibodies against 
HPV-16 proteins have been detected amongh healthy individuals (Hamsikova et 
al 1998). The concomitant of presence of HPV DNA in tumor-free tonsillar tissue 
and seropositivity, however, has not been investigated as yet.   
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6. AIMS OF THE STUDY 
The etiology of HNSCC is considered to be multifactorial. Besides the well-known 
main risk factors, tobacco and alcohol, the presence of some DNA tumor viruses 
as well as the genetic alteration also play a role. An association between infection 
by HPV and HNSCC has been based mainly on the detection of HPV DNA in 
tumor samples and on the case-control studies. Little is known about the physical 
status of HPV in HNSCC, with no systematic study in infection by HPV in tumor-
free tonsillar tissue. Thus far no in vitro model exists to study mechanisms of HPV 
in tonsillar carcinogenesis.  
More specifically, the aims of this thesis were to study: 
1. the role of somatic mutations of PTEN and LKB1 genes in laryngeal tumors 
2. the prevalence, viral load, and physical status of HPV DNA in HNSCC 
3. the frequency of HPV DNA and seroprevalence in patients with tumor-free 
tonsils, and
4. to establish and characterize HPV-16 DNA immortalized HTE cell lines 
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7. PATIENTS, MATERIALS, AND METHODS 
7.1. PATIENTS AND MATERIALS (I, II, III) 
All patients in Studies I, II, and III were from Helsinki University Central 
Hospital, Department of Otorhinolaryngology – Head and Neck Surgery (Table 
5). Fresh tissue obtained from surgical operations and tonsillar exfoliated cells 
collected with Cytobrush Plus Cell Collector (Medscand Medical AB, Sweden) 
into PBS were immediately stored at −70°C till analysis.  
Table 5. Patients and clinical samples 




Laryngeal carcinoma (n=13) 
Study 
I Laryngeal papilloma (n=3), one with 
malignant transformation 
hypopharynx (n = 10) 
larynx (n=18) 
mobile tongue (n = 6) 
base of tongue (n = 9) 





containing at least 
40% neoplastic cells 
Tonsillitis (n = 135)  
Tonsillar hypertrophy (n = 77) 
Fresh-frozen tissue 
containing at least 
30% epithelial cells 
Study 
III









* immunohistochemisty / in situ hybridization 
7.2. CELL LINES (IV) 
Primary human tonsillar epithelial (HTE) cells were derived from children’s 
bilateral tonsillectomies. In these tonsils, HPV-PCR analysis showed no pre-
existing infection with HPV. HTE-114/K1, HTE-114/K2, HTE-114/K3, and HTE-
114/B have derived from HPV-16 immortalized primary HTE cells. The HPV-16 
positive cervical carcinoma cell line SiHa and spontaneously transformed HaCaT 
human keratinocyte cell line were obtained from the American Type Culture 
Collection (ATCC).
nsil (n=5)  to
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7.3. PLASMIDS (IV)  
The plasmids, pHPV16 114/K and pHPV16 114/B, containing full-length HPV-16 
DNA, were the kind gift of Dr. Matthias Dürst, University of Jena, Germany.  
7.4. METHODS 
Method                Described in
DNA extraction from patients’ samples          I, II, III 
Mutation analysis of PTEN and LKB1 genes         I 
Detection and genotype of HPV DNA by PCR       I, III 
Determination of HPV-16 viral load and physical status      III 
Conventional cell culture             IV 
Transfection of cells              IV 
Raft culture                IV 
Anchorage-independent growth in soft agarose        IV 
Tumorigenicity assay              IV 
Electron microscopy examination           IV  
Cytogenetic analysis             IV 
Fluorescence in situ hybridization (FISH)         IV  
Southern blot hybridization             IV 
Northern blot hybridization            IV 
Immunohistochemistry (IHC)            II, IV 
Statistical analysis              II, III 
In situ hybridization (ISH) 
Five-µm sections of formalin-fixed and paraffin-embedded tonsillar SCC tissue 
were deparaffinized and rehydrated. In situ hybridization was performed using 
the Ventana Discovery automated ISH-IHC Slide Stainer (Ventana Medical 
Systems, Inc., Tucson, AZ, USA). The sections were digested with protease 2 
(Ventana) for 4 min before hybridization at 57°C for 14 hours with a Digoxigenin-
labeled full-length HPV-16 DNA probe in ribohybe™ (Ventana) and followed 
with low- and high-stringent wash. The hybrids were detected with the BlueMap 
Detection Kit (Ventana) and counterstained with nuclear Fast Red (Ventana).
After dehydration, the slides were mounted with Eukitt mounting medium (O. 
Kindler GmbH & Co., Freiburg, Germany). The positive signals appeared in blue.  
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8. RESULTS AND DISCUSSION 
8.1. SOMATIC MUTATION IN PTEN AND LKB1 GENES IS A RARE 
EVENT IN LARYNGEAL TUMORS (I) 
To determine whether PTEN and LKB1 tumor suppressor genes are mutated in 
laryngeal tumors, we screened 16 laryngeal tumor samples by genomic 
sequencing and SSCP assay. When we performed direct sequencing of the 
amplicon for PTEN mutations analysis, no mutations were evident in the coding 
sequences and exon/intron boundaries; to screen for LKB1 mutations, the SSCP 
assay was applied after PCR amplification of the nine exons of LKB1. Differences 
in mobility pattern in the SSCP assay are usually suggestive of a variant, the 
nature of which should be examined by sequencing. In our hands, SSCP analysis 
of LKB1 always revealed known mutations, and it is reasonable to assume the 70 
to 80% sensitivity that is commonly reported for the method (Jordanova et al
1997). Our SSCP protocol was specifically optimized for the LKB1 gene analysis. 
To validate the SSCP results, exon 1 was directly sequenced from each sample 
with no mutations observed in exon 1 and the respective exon/intron boundaries. 
The methods we used to detect mutations would not have detected some 
mutation types, such as large genomic deletions or alterations in the promoter 
region.  
Several tumor suppressor genes have been demonstrated to play an important 
role in human tumors, including head and neck cancers. Our results are in 
agreement with reports showing that in HNSCC, somatic mutations in PTEN gene 
are infrequent (Henderson et al 1998; Gasparotto et al 1999; Hu et al 1999; Chen et 
al 2000; Mavros et al 2002). Other studies, however, imply that mutation of PTEN
might play a role in the genesis of some HNSCC, ie., carcinomas of the 
oropharynx, larynx, and hypophaynx (Okami et al 1998; Shao et al 1998; Poetsch et 
al 2002). Analysis of PTEN expression at protein level is probably more relevant 
for the elucidation of its role in head and neck tumors. In laryngeal papillomas, 
PTEN protein is consistently overexpressed (Zhang and Steinberg 2000). Levels of 
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PTEN protein vary from negative to highly expressed in SCC of the tongue and 
oral cavity, and loss of PTEN expression is significantly associated with poorer 
prognosis (Lee et al 2001; Squarize et al 2002). The rate of PTEN inactivation at 
protein level may be more frequent than that identified at the genomic level in 
HNSCC, and the inactivation of PTEN by either genetic alteration or by the loss of 
a PTEN transcript may play a role in the pathogenesis of some oral cancer (Shin et 
al 2002).
8.2. PREVALENCE AND PHYSICAL STATUS OF HPV IN HNSCC (II) 
8.2.1. Prevalence, genotype, viral load, and physical status of HPV DNA in 
HNSCC
By SPF10 PCR screening and INNO-LiPA HPV genotyping assay, we found that 
61% (37 of 61) of the tumors of HNSCC patients harbored HPV DNA. The most 
frequently detected type was HPV-16, followed by HPV-33 (Table 6). None of our 
samples were positive for the cutaneous HPVs. Our findings support the role of 
high-risk types of HPV, especially HPV-16, in head and neck carcinogenesis. In 
line with other reports (Snijders et al 1992; Paz et al 1997; Mellin et al 2000; 
Klussmann et al 2001), we also observed a high prevalence of high-risk HPV-DNA 
in tonsillar carcinoma (n = 5, 100%). We were able to demonstrate by ISH that 
HPV-16 DNA was localized only in tumor cells of a tonsillar SCC (Fig 4).
Figure 4. Photomicrograph shows that HPV-16 DNA (in blue) located in poorly 
differentiated dysplastic epithelial cells in tonsillar SCC. Magnification × 400. 
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Hypopharynx (10) 2 1 1 1 0 0 5 (50) 
Larynx (18) 5 0 1 2 1 0 9 (50) 
Base of tongue (9) 2 4 0 1 0 0 7 (8) 
Mobile tongue (6) 3 0 0 1 0 0 4 (7) 
Oral cavity (13) 6 0 0 0 0 1 7 (54) 
Tonsil (5) 5 0 0 0 0 0 5 (100) 
Total (61) 23 5 2 5 1 1 37 (61) 
Viral load of HPV-16 DNA in HNSCC was analyzed by real-time PCR. Even 
considering that some differences existed in the proportion of carcinoma cells (40 
to 100%) and in the amount of material used for DNA extraction, large variation 
appeared in the viral load between tonsillar SCC and non-tonsillar HNSCC. The 
median viral load in tonsillar specimens was thus approximately 80,000 times as 
high as in non-tonsillar HNSCC specimens (Fig 2, Study II). Furthermore, the 
median viral load in tonsillar SCC that harbored episomal viral DNA was 11.6 
times that in the integrated group. This high viral load of HPV-16 DNA in 
tonsillar carcinomas has also been observed by others (Table 7). High viral load in 
tonsillar SCC favors detection of HPV, and this might explain the high prevalence 
of HPV-DNA in tonsillar SCC samples. It is unclear why the viral load in tonsillar 
carcinomas is markedly higher than at other sites of HNSCC.  
Table 7. Viral load in HNSCC 
Site of tumor HPV-16 DNA (copies/genome) 
2.3 – 245 (Table II, study II) 
10 – 15,400 (Mellin et al 2002) Tonsillar SCC 
6.6 × 10-4 – 172 (Klussmann et al 2001) 
HNSCC (mainly oropharyngeal SCC) 1.8 × 10-2 – 322 (Ha et al 2002) 
Non-tonsillar HNSCC 5 × 10-5 – 3.4 × 10-2 (II) 
Table 6. Frequency and genotypes of HPV DNA in 61 HNSCC patients 
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Viral DNA integration often leads to the disruption of E1/E2 genes in HPV-
associated cervical lesions (Kalantari et al 1998). In our study, determination of 
viral physical status was based on the assumption that the E2 gene is disrupted in 
integrated viral DNA. Thus, episomal viral DNA has equivalent copy numbers of 
the E2 and the E6 genes, and mixed forms have smaller copy numbers of the E2 
than of the E6 (Peitsaro et al 2002). We observed that HPV-16 DNA existed in all 
three forms: only episomal (n = 8), only integrated (n = 11), and mixed (n = 4). The 
disrupted E2 gene is quite common in our study: 15 of 25 (60%). The minor 
disadvantages of our assay for determination of viral physical status stem from 
the assumptions that viral integration occurs within the selected site of the E2 
gene and no mutations exist at sites of PCR primers of E2 region. Although 
disruption of the E2 gene has been considered as consequence of viral integration, 
episomal viral DNA with no detectable E2 DNA also occurs in tonsillar SCC 
(Mellin et al 2002).
8.2.2. Absence of viral capsid protein expression in HNSCC 
Despite the high copy numbers of episomal HPV-16 DNA in tonsillar carcinomas, 
HPV L1 capsid protein was surprisingly undetectable by immunohistochemistry 
in any of the 36 HPV-positive tissue sections, whereas it was expressed strongly in 
control samples from a cervical intra-epithelial neoplasia type III and in a 
juvenile-onset laryngeal papilloma. Thus, undetectable HPV L1 protein in our 
tonsillar SCC samples was not due to technical reasons. It would, however, be of 
interest to look at L1 mRNA expression in the HPV-containing tonsillar SCC 
samples. In tonsillar carcinoma, HPV was reported to be correlated with a poor 
differentiation, no terminal differentiation, and basaloid histological appearance 
(Klussmann et al 2001; Wilczynski et al 1998). Our observation supports the view 
that the expression of viral capsid proteins requires terminal differentiation of 
host cells.
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8.2.3. Correlation of HPV DNA status and clinical outcome 
Figure 5. Kaplan-Meier survival graph showing that patients harbouring HPV-
positive HNSCC had a similar survival profile as the HPV-negative patients. 
Fifty-nine HNSCC patients were included in the analysis.  
By Kaplan-Meier survival analysis, we observed that HPV-positive patients 
had similar survival profile as the HPV-negative ones (Fig 5). Viral load had no 
statistically significant effect on the survival among those patients with HPV-16 
positive HNSCC specimens (data not shown). Interestingly, we found that large 
tumors (T3 and T4) were significantly over-represented among the samples 
harboring episomal HPV-16 DNA, as compared to those which contained 
integrated or mixed forms of the viral DNA (Fig 3, Study II). However, the 
number of patients was rather small, and follow-up time quite short. Reports on 
the impact of HPV-positivity on prognosis in HNSCC have been controversial.
Some studies reported that the prognosis of patients is not correlated with the 
detection of HPV DNA or with the viral physical status (Pintos et al 1999; 
Badaracco et al 2000). Others, however, observed that patients with HPV-positive 
HNSCC had a better overall and disease-specific survival than did the HPV-
negative group (Ringstrom et al 2002). This correlation has also been observed 
HPV positive group 
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among tonsillar carcinoma patients, plus the fact that higher viral load correlated 
with better clinical outcome in tonsillar SCC harboring episomal HPV-16 (Mellin
et al 2002). The number of cases in those studies was relatively small (11 to 101). 
Thus, large study populations and a long follow-up time are required for 
clarificaton of this issue. 
8.3. PRESENCE OF HPV-16 DNA BUT NO OTHER TYPES IN TUMOR-
FREE TONSILS (III) 
8.3.1. Presence of HPV DNA and HPV genotypes in tumor-free tonsils 
We analyzed HPV DNA in tumor-free tonsillar tissue by nested PCR using the 
consensus primers My09/11 and GP5+/6+; the overall prevalence of HPV-16 
DNA in tonsillar tissue was 6.1% (13 of 212) in patients operated on for tonsillitis 
or tonsillar hypertrophy, and no other type of HPV was detectable (Table 1a, 
Study III). No significant difference was observed between the positivity of HPV 
DNA in patients with tonsillitis (7.%, 10 of 135) and tonsillar hypertrophy (3.9%, 
3 of 77). In contrast, only one tonsillar exfoliated cell sample from 189 control 
subjects with normal tonsils had detectable HPV DNA, and this one was typed as 
HPV-58. Thus, the presence of HPV-DNA in tonsillar tissue was significantly 
higher (p < 0.05, Fisher’s exact test, two-tailed) than that in tonsillar exfoliated 
cells. The frequency of HPV DNA in normal tonsils or tonsillitis was summarized 
in a recent review that out of 200 samples from 10 original studies, 6% (12 of 200) 
were positive for HPV-16 and 2.5% (5 of 200) were positive for HPV-6/11, thus, 
the overall frequency of HPV DNA was 8.5% (17 of 200) (Syrjänen 2004).  
Since in our study the samples from patients and control subjects were not 
obtained in the same way, we were not able to determine the concordance of 
HPV-DNA positivity in tonsillar tissue and that in tonsillar exfoliated cells. Data 
on this are controversial. One study showed a lower prevalence of HPV DNA in 
oral exfoliated cells, scraped superficially with soft toothbrushes, than that in oral 
biopsies among HNSCC patients (Herrero et al 2003). These authors suggested 
that the HPV status in exfoliated cells did not accurately reflect that in the tumor; 
however, other study observed that 57.9% of the patients (n = 190) with cancer of 
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oral cavity or oropharynx were positive for HPV in both tumor tissue and oral 
exfoliated cells, collected by oral rinse, indicating good correlation of HPV-DNA 
positivity from tumor tissue and that from oral exfoliated cells (Smith et al 2004). 
Reliability of the exfoliated cells for analysis of HPV DNA by PCR needs to be 
evaluated further regarding the sampling methods, tumor or tumor-free samples, 
and specific anatomic sites of the head and neck. 
Interestingly, in our study viral DNA prevalence was highest in preschool 
children aged between 1.5 and 6 years (11.5%, 3 of 26) among all age groups. It is 
unknown how these children originally acquired the HPV-16 DNA in their 
tonsils. Vertical transmission of HPV from mothers to their children, or additional 
sources such as breast milk, siblings via kissing, or exposure to contaminated 
fomites is feasible, as suggested in one review (Syrjänen and Puranen 2000). In 
our study population, no patients older than 33 years was positive for HPV DNA 
in their tonsils, allowing speculation that, if these patients did not develop pre-
cancer or cancer lesions, HPV-16 DNA had been cleared by their immune system. 
Infection by HPV is common, but it rarely develops into cancer (Bauer et al 1991).
8.3.2. Seroprevalence of antibodies against HPV-16 L1, E6, and E7 
The overall seroprevalence of HPV-16 L1 was 11.8% (25 of 212) in patients group 
and 8.5% (16 of 189) in control subjects (Table 1, Study III). The highest 
seroprevalence appeared in the group aged between 26 and 40 years in both 
patients and control subjects, but not significantly. It is unknown whether these 
patients and control subjects had had HPV infection at sites other than their 
tonsils, since the HPV-16 L1 antibody can persist for many years and is a marker 
for persistant infection by HPV-16 (Shah et al 1997; af Geijersstam et al 1998), and 
in females is associated with lifetime number of sexual partners (Dillner et al
1996). Although serum antibodies against HPV-16 E6 and E7 proteins were 
detectable in our patients and control subjects, prevalences were low (0 to 2.8%) 
(Table 1, Study III). Detection of serum antibodies against HPV-16 E6 and E7 
proteins among all age healthy individuals has been observed by several studies 
(Muller et al 1995; Mund et al 1997; Hamsikova et al 1998). Antibody responses to 
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HPV-16 E6 and E7 fusion proteins are intriguing, because these E6 and E7 genes 
are involved in HPV-mediated cellular transformation, and such antibodies are 
markers for HPV-16 associated oropharyngeal cancer (Zumbach et al 2000; 
Herrero et al 2003).
8.3.3. Non-concordance between presence of HPV DNA in tonsillar tissue 
and seropositivity to HPV proteins 
Double positivity of HPV-16 DNA in tonsillar tissue and serum antibodies against 
any HPV-16 proteins was apparent in 2 of 212 patients; both were male young 
adults and had elevated serum antibodies against HPV-16 L1 proteints (all 
coefficients < 0.10, all p > 0.4, Spearman correlation coefficients). No concordance 
thus exists between the presence of HPV-16 DNA in tumor-free tonsillar tissue 
and seropositivity against HPV-proteins. Our patients’ HPV-16 DNA was 
detected at only one visit, and we lack knowledge of how long the HPV DNA had 
been in their tonsillar tissue and whether it was a transient infection. A single 
detection of viral DNA is less likely to lead to seroconvertion than is the case for 
patients in whom HPV-16 DNA is detectable at several visits (Carter et al 2000; 
Carter et al 1995; Carter et al 1996; de Gruijl et al 1997). Most HPV-16 
seroconversions were detected 6 to 12 months after detection of HPV-16 DNA, 
and transient HPV-DNA is associated with a failure to seroconvert following 
incident HPV infection (Carter et al 2000). Conversely, those seropositive patients 
with no detectable HPV DNA in their tonsils may harbor the viral DNA at other 
anatomic sites than one of their tonsils. 
8.4. ESTABLISHMENT AND CHARACTERIZATION OF HPV-16 DNA 
IMMORTALIZED HUMAN TONSILLAR EPITHELIAL CELL LINES (IV) 
8.4.1. Growth and differentiation of HPV-16 DNA transfected human 
tonsillar epithelial cells 
The introduction of full-length HPV-16 plasmid with its own promotors, 114/K or 
114/B, into primary human tonsillar epithelial (HTE) cells from two donors, 
respectively, resulted in cell infinite growth. The immortalization properties of 
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HPV-16 have been mapped to oncogenes E6 and E7 (Hawley-Nelson et al 1989; 
Liu et al 1999). Subculturing HPV-transfected HTE cells on plastic dishes revealed 
no significant changes in cellular morphology. In vitro, the differentiated 
phenotype of epithelial cells can be induced by growing cells at the air-liquid 
interface on collagenous substrata. If HPV-immortalized cells represent the tissue 
culture counterpart to naturally occurring premalignant cells, they should share 
many characteristics of dysplastic cells (Blanton et al 1991). We therefore used a 
raft culture system, which reproduces in vitro the differentiation patterns of 
epithelial cells in vivo, to search for the differences between normal and HPV-
transfected HTE cells. We observed that the appearance of the HPV-16 transfected 
HTE cells in raft culture varied considerably in size and shape from the primary 
HTE cells. They showed disturbed cellular polarity, vacuolated cytoplasm, and an 
increased nucleus-to-cytoplasm ratio which resembled epithelial dysplasia in vivo.
A weak-to intermediate expression level of cytokeratins (determined with pan 
cytokeratins 1, 5, 10, and 14) was detected in the HPV-transfected cells in rafts (Fig 
2, Study IV). The poor differentiation of HPV-transformed cells was possibly a 
result of the expression of viral oncogenes E6 and E7 which stimulate cell 
proliferation in raft culture and leads to the formation of disorganized epithelial 
layers (Halbert et al 1992). By electron microscopy, we observed that HPV-16 
transfected HTE cell lines presented numerous desmosomes and microvilli, 
characteristic components of epithelial cells.
8.4.2. Tumorigenicity of HPV-16 transformed cell lines 
All HPV-transformed HTE cells failed to form colonies in soft agarose and tumors 
in nude mice, suggesting that HPV-transformed cells are non-malignant. The 
presence of HPV alone does not necessarily result in malignancy. Other co-factors 
may be necessary for full oncogenic expression, of which fibroblasts are perhaps 
one of the most important (Zheng and Vaheri 1995; Atula et al 1997; Olumi et al
1999). We also observed that a co-culture of HES fibroblasts with HPV-
transformed HTE cells in soft agarose resulted in colony formation (Fig 6). Several 
growth factors are known to modulate cascades of signaling pathways in 
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epithelial cell lines. Dysregulation of such cascades may lead to cell 
transformation and tumorigenesis (Ridley et al 1995; Dhawan et al 1999; 
LaRochelle et al 1999). For example, upregulation of keratinocyte growth factor 
(KGF) receptor in HPV-immortalized cells may subsequently result in KGF-
induced anchorage-independent growth of the cells (Zheng et al 1995). KGF is a 
member of the fibroblast growth factor family and has unique target-cell 
specificity restricted to the epithelial cell type (Finch et al 1989; Aaronson et al
1991).
Figure 6. HES fibroblasts induced anchorage-independent growth of HPV-
transformed HTE cells in soft agarose. a. Co-culture of HPV-transformed HTE cells 
and HES fibroblasts formed large colonies (arrow) in soft agarose. b. Culture of only 
HPV-transformed cells in soft agarose formed no colony. 
8.4.3. Cytogenetic aberration 
Unbanded metaphase spreads from all HPV-16 transfected HTE cell lines showed 
chromosome abnormalities such as chromosomal breakage, chromatid elongation 
(premature chromosome condensation), dicentric and acentric chromosomes, and 
numerical chromosomal changes (n = 80 − 100) (Fig 4, Study IV). Our observations 
are in line with that by others (Dürst et al 1987a; Hukku et al 2000). Mechanisms 
underlying HPV integration and chromosomal instability need to be further 
studied.
a b
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8.4.4. Physical status and chromosomal localization of viral DNA in HPV-16 
transformed HTE cell lines 
Southern blot analysis indicated that all four HPV-transformed HTE cell lines 
harbored only integrated HPV-16 DNA (Fig 5, Study IV). We used real-time PCR 
with primers (Table 1, Study II) specific for the HPV-16 E2 and E6 regions to 
quantitate the copy numbers of the E2 and E6 DNA and found that each cell line 
contained equal amounts of E2 and E6 DNA copies, suggesting that integration 
did not occur within the selected E2 region. Although the E2 gene is often 
disrupted upon viral DNA integration in vivo (Kalantari et al 1998), integration 
sites do not necessary occur within the E2 gene in vitro transfection. The viral 
DNA integrated exclusively at chromosomal 7q31 in three cell lines originating 
from the same transfectant (HTE-114/K); and in a polyclonal cell line from 
another transfectant of a different donor (HTE-114/B), the viral DNA integrated 
at single locus near the telomere of the long arm of chromosome 9 (Fig 6, study 
IV). According to previous reports viral DNA integration sites seem to be random: 
Kahn and colleagues reported a tonsillar carcinoma case with HPV-6a integration 
at chromosomal 10q24 in tumor cells (Kahn et al 1994). In cervical carcinomas, 
integration of HPV has been mapped in many chromosomes, i.e., chromosomes 1, 
2, 3, 6, 8, 10, 13, 14, 16, 17, 18, 20, and 22, with the integration event occurring at a 
single locus in each case (Dürst et al 1987b; Wilke et al 1996; Reuter et al 1998; 
Koopman et al 1999; Thorland et al 2000; Luft et al 2001). However, multi-site 
integration has also been evident in a cell line derived from oral carcinoma 
containing six viral integrated loci within chromosomal region 15q14-15 and five 
unidentifiable chromosomes (Steenbergen et al 1995). Several studies have 
reported no specific preferred chromosomal sites for viral DNA integration in 
HPV-immortalized cell lines (Weijerman et al 1997; Dürst et al 1995; Smith et al
1992; Popescu and DiPaolo 1990). In those studies, the authors also observed that 
viral DNA integrated in either a single locus or multi-site in chromosomes. It is 
unclear whether host-cell origin, HPV variants, transfection condition, or any 
combination of these may favor specific loci for viral integration.
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8.4.5. Viral gene expression in HPV-16 transformed HTE cell lines  
The viral DNA was transcriptionally active in all transfected cells. Two major 
transcripts of 1.7 and 3.7 kb and one minor transcript of 2.4 kb existed in all four 
immortalized cell lines by northern blot hybridization with a full-length HPV-16 
DNA probe as well as with an E7 specific probe (Fig 7, Study IV). In contrast, no 
viral transcript was detectable when the filter was hybridized with a fragment 
corresponding to the L1 region. We failed to demonstrate viral particles in the raft 
culture, which can be explained by the fact that these cells contained no episomal 
viral DNA. Viral particles have been identified in raft cultured cells derived from 
a cervical intraepithelial neoplasia type I lesion and HPV-immortalized 
keratinocytes containing episomal viral DNA (Meyers et al 1992; Frattini et al
1996). When a constructed chimeric HPV-18/16 plasmid DNA was introduced 
into primary keratinocytes and maintained episomally, the viral late functions 
(capsid gene expression and synthesis of virion) were active in raft cultures 
(Meyers et al 2002). 
Our HPV-immortalized HTE cells are non-malignant and thus provide a 
useful in vitro model for studying further the multistep molecular events of HPV-
16 associated tonsillar carcinogenesis, as well as the effect of anti-virus and anti-
tumor compounds. 
Human papillomavirus type 16 in head and neck carcinogenesis 42
9. CONCLUDING REMARKS 
The studies presented in this thesis have shown the following:  
• Although mutations in many tumor suppressor genes play a role in head and 
neck carcinogenesis, our study suggests that PTEN and LKB1 are not among 
them in laryngeal tumors. 
• Infection by high-risk types of HPV plays a role in the development of head 
and neck cancers, particularly in tonsillar carcinogenesis. HPV-16 DNA 
existed in episomal, integrated, and mixed forms in HNSCC. Tonsillar SCC 
harbored a remarkably higher viral load than did the others in HNSCC. 
Patients with HPV-positive tumors had a prognosis similar to those with HPV-
negative ones.  
• Only HPV-16 DNA, but no other types, presented in tumor-free tonsillar 
tissue. Detection of HPV-16 DNA in tonsillar tissue did not correlate with 
seropositivity against HPV proteins. HPV DNA is seldom detected in the 
exfoliated tonsillar cells in normal tonsils, suggesting that tonsillar crypt 
epithelial cells may be a reservoir for HPV-16 or normal tonsils seldom harbor 
HPV.
• Primary human tonsillar epithelial cells can be immortalized by introduction 
of full-length HPV-16 DNA which provides an in vitro model to study further 
multistep molecular events of HPV-16 associated tonsillar carcinogenesis, as 
well as treatment for the HPV-associated tonsillar carcinomas. 
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10. PERSPECTIVES 
Detection of HPV DNA in tumor or precancer samples does not on its own 
indicate that the virus plays a causal role in tumor development. Additional 
molecular data argue, however, that the virus may play such a role in a subset of 
HNSCC. Understanding the fundamental molecular changes of HNSCC may lead 
to improvements in therapy for patients with this disease.  
Studies on the molecular mechanisms underlying HPV-associated head and 
neck carcinogenesis is hindered, because the HPV is not easy to propagate in vitro.
We have established and characterized HPV-immortalized human tonsillar 
epithelial cell lines which allow us to further study multistep in molecular events 
(co-factors) in HPV-16 associated tonsillar carcinogenesis. In addition, these cell 
lines may provide an in vitro model to test effects of anti-viral and anti-tumor 
agents, as well as to study the response to radiotherapy.  
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